Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis

David Warr, Andrew Willan, Sheldon Fine, Kenneth Wilson, Alan Davis, Charles Erlichman, James Rusthoven, Wycliffe Lofters, David Osoba, Francis Laberge, Jean Latreille, Joseph Pater

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Trials of selective 5-hydroxytryptamine3 receptor antagonists have shown excellent antiemetic activity for chemotherapy containing cisplatin when compared with high-dose metoclopramide. There is little information about the efficacy of these new agents for chemotherapy other than for high-dose cisplatin. We performed a double-blind, randomized trial comparing a single dose of the 5-hydroxytryptamine3 receptor antagonist granisetron (BRL 43694A) as a single intravenous dose with dexamethasone plus prochlorperazine in 152 patients receiving their first course of moderately emetogenic chemotherapy (mainly doxorubicin-and cyclophosphamide-containing combinations). During the first 24 hours, there was a statistically significant advantage for the granisetron group in terms of the prevention of both nausea and emesis. There was no difference in the frequency of reported adverse events. We conclude that granisetron is more effective than dexamethasone plus prochlorperazine in patients who are receiving moderately emetogenic cytotoxic agents.

Original languageEnglish (US)
Pages (from-to)1169-1173
Number of pages5
JournalJournal of the National Cancer Institute
Volume83
Issue number16
StatePublished - Aug 21 1991
Externally publishedYes

Fingerprint

Prochlorperazine
Granisetron
Chemotherapy
Dexamethasone
Vomiting
Dose
Cisplatin
Drug Therapy
Receptor
Nausea
Randomized Trial
Metoclopramide
Antiemetics
Cytotoxins
Doxorubicin
Cyclophosphamide
Efficacy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Radiology Nuclear Medicine and imaging

Cite this

Warr, D., Willan, A., Fine, S., Wilson, K., Davis, A., Erlichman, C., ... Pater, J. (1991). Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. Journal of the National Cancer Institute, 83(16), 1169-1173.

Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. / Warr, David; Willan, Andrew; Fine, Sheldon; Wilson, Kenneth; Davis, Alan; Erlichman, Charles; Rusthoven, James; Lofters, Wycliffe; Osoba, David; Laberge, Francis; Latreille, Jean; Pater, Joseph.

In: Journal of the National Cancer Institute, Vol. 83, No. 16, 21.08.1991, p. 1169-1173.

Research output: Contribution to journalArticle

Warr, D, Willan, A, Fine, S, Wilson, K, Davis, A, Erlichman, C, Rusthoven, J, Lofters, W, Osoba, D, Laberge, F, Latreille, J & Pater, J 1991, 'Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis', Journal of the National Cancer Institute, vol. 83, no. 16, pp. 1169-1173.
Warr, David ; Willan, Andrew ; Fine, Sheldon ; Wilson, Kenneth ; Davis, Alan ; Erlichman, Charles ; Rusthoven, James ; Lofters, Wycliffe ; Osoba, David ; Laberge, Francis ; Latreille, Jean ; Pater, Joseph. / Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. In: Journal of the National Cancer Institute. 1991 ; Vol. 83, No. 16. pp. 1169-1173.
@article{7dff0f626b5b4bf691b55400b2a120f5,
title = "Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis",
abstract = "Trials of selective 5-hydroxytryptamine3 receptor antagonists have shown excellent antiemetic activity for chemotherapy containing cisplatin when compared with high-dose metoclopramide. There is little information about the efficacy of these new agents for chemotherapy other than for high-dose cisplatin. We performed a double-blind, randomized trial comparing a single dose of the 5-hydroxytryptamine3 receptor antagonist granisetron (BRL 43694A) as a single intravenous dose with dexamethasone plus prochlorperazine in 152 patients receiving their first course of moderately emetogenic chemotherapy (mainly doxorubicin-and cyclophosphamide-containing combinations). During the first 24 hours, there was a statistically significant advantage for the granisetron group in terms of the prevention of both nausea and emesis. There was no difference in the frequency of reported adverse events. We conclude that granisetron is more effective than dexamethasone plus prochlorperazine in patients who are receiving moderately emetogenic cytotoxic agents.",
author = "David Warr and Andrew Willan and Sheldon Fine and Kenneth Wilson and Alan Davis and Charles Erlichman and James Rusthoven and Wycliffe Lofters and David Osoba and Francis Laberge and Jean Latreille and Joseph Pater",
year = "1991",
month = "8",
day = "21",
language = "English (US)",
volume = "83",
pages = "1169--1173",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "16",

}

TY - JOUR

T1 - Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis

AU - Warr, David

AU - Willan, Andrew

AU - Fine, Sheldon

AU - Wilson, Kenneth

AU - Davis, Alan

AU - Erlichman, Charles

AU - Rusthoven, James

AU - Lofters, Wycliffe

AU - Osoba, David

AU - Laberge, Francis

AU - Latreille, Jean

AU - Pater, Joseph

PY - 1991/8/21

Y1 - 1991/8/21

N2 - Trials of selective 5-hydroxytryptamine3 receptor antagonists have shown excellent antiemetic activity for chemotherapy containing cisplatin when compared with high-dose metoclopramide. There is little information about the efficacy of these new agents for chemotherapy other than for high-dose cisplatin. We performed a double-blind, randomized trial comparing a single dose of the 5-hydroxytryptamine3 receptor antagonist granisetron (BRL 43694A) as a single intravenous dose with dexamethasone plus prochlorperazine in 152 patients receiving their first course of moderately emetogenic chemotherapy (mainly doxorubicin-and cyclophosphamide-containing combinations). During the first 24 hours, there was a statistically significant advantage for the granisetron group in terms of the prevention of both nausea and emesis. There was no difference in the frequency of reported adverse events. We conclude that granisetron is more effective than dexamethasone plus prochlorperazine in patients who are receiving moderately emetogenic cytotoxic agents.

AB - Trials of selective 5-hydroxytryptamine3 receptor antagonists have shown excellent antiemetic activity for chemotherapy containing cisplatin when compared with high-dose metoclopramide. There is little information about the efficacy of these new agents for chemotherapy other than for high-dose cisplatin. We performed a double-blind, randomized trial comparing a single dose of the 5-hydroxytryptamine3 receptor antagonist granisetron (BRL 43694A) as a single intravenous dose with dexamethasone plus prochlorperazine in 152 patients receiving their first course of moderately emetogenic chemotherapy (mainly doxorubicin-and cyclophosphamide-containing combinations). During the first 24 hours, there was a statistically significant advantage for the granisetron group in terms of the prevention of both nausea and emesis. There was no difference in the frequency of reported adverse events. We conclude that granisetron is more effective than dexamethasone plus prochlorperazine in patients who are receiving moderately emetogenic cytotoxic agents.

UR - http://www.scopus.com/inward/record.url?scp=0025862327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025862327&partnerID=8YFLogxK

M3 - Article

C2 - 1653363

AN - SCOPUS:0025862327

VL - 83

SP - 1169

EP - 1173

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 16

ER -